142 related articles for article (PubMed ID: 17627537)
21. Heparin Mimetics: Their Therapeutic Potential.
Mohamed S; Coombe DR
Pharmaceuticals (Basel); 2017 Oct; 10(4):. PubMed ID: 28974047
[TBL] [Abstract][Full Text] [Related]
22. Retinal and choroidal angiogenesis: a review of new targets.
Cabral T; Mello LGM; Lima LH; Polido J; Regatieri CV; Belfort R; Mahajan VB
Int J Retina Vitreous; 2017; 3():31. PubMed ID: 28835854
[TBL] [Abstract][Full Text] [Related]
23. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Yang S; Zhao J; Sun X
Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
[TBL] [Abstract][Full Text] [Related]
24. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.
Berardi R; Morgese F; Torniai M; Savini A; Partelli S; Rinaldi S; Caramanti M; Ferrini C; Falconi M; Cascinu S
World J Gastrointest Oncol; 2016 Apr; 8(4):389-401. PubMed ID: 27096034
[TBL] [Abstract][Full Text] [Related]
25. Profile of nintedanib in the treatment of solid tumors: the evidence to date.
Awasthi N; Schwarz RE
Onco Targets Ther; 2015; 8():3691-701. PubMed ID: 26677336
[TBL] [Abstract][Full Text] [Related]
26. A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.
Fan L; Li W; Ying S; Shi L; Wang Z; Chen G; Ye H; Wu X; Wu J; Liang G; Li X
Tumour Biol; 2015 Sep; 36(9):7233-41. PubMed ID: 25894376
[TBL] [Abstract][Full Text] [Related]
27. Targeting angiogenesis in advanced cervical cancer.
Eskander RN; Tewari KS
Ther Adv Med Oncol; 2014 Nov; 6(6):280-92. PubMed ID: 25364393
[TBL] [Abstract][Full Text] [Related]
28. Study of the association of adrenomedullin and basic-fibroblast growth factors with the peripheral arterial blood flow and endothelial dysfunction biomarkers in type 2 diabetic patients with peripheral vascular insufficiency.
Alrouq FA; Al-Masri AA; Al-Dokhi LM; Alregaiey KA; Bayoumy NM; Zakareia FA
J Biomed Sci; 2014 Oct; 21(1):94. PubMed ID: 25287126
[TBL] [Abstract][Full Text] [Related]
29. Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2.
Tanaka M; Yamaguchi M; Shiota M; Kawamoto Y; Takahashi K; Inagaki A; Osada-Oka M; Harada A; Wanibuchi H; Izumi Y; Miura K; Iwao H; Ohkawa Y
Monoclon Antib Immunodiagn Immunother; 2014 Aug; 33(4):261-9. PubMed ID: 25171006
[TBL] [Abstract][Full Text] [Related]
30. A novel FGF2 antagonist peptide P8 with potent antiproliferation activity.
Fan L; Xie H; Chen L; Ye H; Ying S; Wang C; Wu X; Li W; Wu J; Liang G; Li X
Tumour Biol; 2014 Oct; 35(10):10571-9. PubMed ID: 25062723
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.
Wu J; Ji J; Weng B; Qiu P; Kanchana K; Wei T; Wang Y; Cai Y; Li X; Liang G
Oncotarget; 2014 Jun; 5(12):4543-53. PubMed ID: 24980830
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation.
Wu X; Huang H; Wang C; Lin S; Huang Y; Wang Y; Liang G; Yan Q; Xiao J; Wu J; Yang Y; Li X
Oncotarget; 2013 Oct; 4(10):1819-28. PubMed ID: 24142482
[TBL] [Abstract][Full Text] [Related]
33. Anti-Inflammatory, Antioxidant, Anti-Angiogenic and Skin Whitening Activities of Phryma leptostachya var. asiatica Hara Extract.
Jung HJ; Cho YW; Lim HW; Choi H; Ji DJ; Lim CJ
Biomol Ther (Seoul); 2013 Jan; 21(1):72-8. PubMed ID: 24009862
[TBL] [Abstract][Full Text] [Related]
34. Current status of bevacizumab in advanced ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Panici PB; Venezia M; Tomao S
Onco Targets Ther; 2013; 6():889-99. PubMed ID: 23901283
[TBL] [Abstract][Full Text] [Related]
35. Fucoidan inhibits the growth of hepatocellular carcinoma independent of angiogenesis.
Zhu C; Cao R; Zhang SX; Man YN; Wu XZ
Evid Based Complement Alternat Med; 2013; 2013():692549. PubMed ID: 23737842
[TBL] [Abstract][Full Text] [Related]
36. A novel role for inducible Fut2 in angiogenesis.
Tsou PS; Ruth JH; Campbell PL; Isozaki T; Lee S; Marotte H; Domino SE; Koch AE; Amin MA
Angiogenesis; 2013 Jan; 16(1):195-205. PubMed ID: 23065099
[TBL] [Abstract][Full Text] [Related]
37. Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.
Rusnati M; Bugatti A; Mitola S; Leali D; Bergese P; Depero LE; Presta M
Sensors (Basel); 2009; 9(8):6471-503. PubMed ID: 22454596
[TBL] [Abstract][Full Text] [Related]
38. Gekko-sulfated glycopeptide inhibits tumor angiogenesis by targeting basic fibroblast growth factor.
Zhang SX; Zhu C; Ba Y; Chen D; Zhou XL; Cao R; Wang LP; Ren Y; Wu XZ
J Biol Chem; 2012 Apr; 287(16):13206-15. PubMed ID: 22371501
[TBL] [Abstract][Full Text] [Related]
39. Blood vessels as targets in tumor therapy.
Claesson-Welsh L
Ups J Med Sci; 2012 May; 117(2):178-86. PubMed ID: 22348394
[TBL] [Abstract][Full Text] [Related]
40. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.
Kono SA; Heasley LE; Doebele RC; Camidge DR
Curr Cancer Drug Targets; 2012 Feb; 12(2):107-23. PubMed ID: 22165970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
